Arrowhead Reports Positive Late-Stage Trial Results for Lipid Drug, Impacting Rival Ionis Pharmaceuticals
Arrowhead Pharmaceuticals (ARWR) announced positive late-stage trial results for its lipid-lowering drug plozasiran in patients with severe hypertriglyceridemia. The news negatively impacted shares of rival company Ionis Pharmaceuticals (IONS), which markets a competing therapy approved by the FDA.
